Summary of Minerva Neurosciences Conference Call Company Overview - **Company**: Minerva Neurosciences (NasdaqCM:NERV) - **Focus**: Development of roluperidone, a potential treatment for schizophrenia, specifically targeting negative symptoms [1][2] Industry Context - **Schizophrenia Symptoms**: Schizophrenia is characterized by three types of symptoms: positive, negative, and cognitive deficits. Negative symptoms significantly impair quality of life and are currently not effectively treated by existing antipsychotics [2][3][4] - **Negative Symptoms**: These include avolition (lack of motivation), which is crucial for patient functioning and quality of life. Current treatments do not address these symptoms adequately, leading to a significant unmet medical need [5][6][7] Core Points and Arguments - **Treatment Gap**: There is no approved treatment for negative symptoms of schizophrenia in the U.S. as of now, and existing antipsychotics may worsen these symptoms [4][5] - **Clinical Trial Design**: The company emphasizes the need for innovative trial designs to assess the efficacy of treatments for negative symptoms, suggesting that traditional methods may not be suitable [8][9] - **Pharmacology of Roluperidone**: Roluperidone works through mechanisms that do not block dopamine, which is believed to help maintain stability in positive symptoms while improving negative symptoms [16][17] - **Efficacy Data**: In clinical trials, roluperidone showed significant improvements in negative symptoms and functioning, with a low relapse rate when used as monotherapy. The drug was well-tolerated with no significant side effects [22][24][23] Important Data Points - **Clinical Trial Results**: - The primary endpoint was assessed using the PANSS scale, with significant improvements noted at week 12. The 64 mg dose showed stronger effects compared to the 32 mg dose [19][20] - The first study had a p-value of 0.0001, indicating strong efficacy, while the second study showed a nominal improvement for the 64 mg dose [20][21] - **Patient Population**: Over 800 patients participated in the trials, with a focus on those with stable positive symptoms and significant negative symptoms [17] Regulatory Considerations - **FDA Interactions**: The company has engaged in discussions with the FDA regarding trial design and endpoints, aiming to establish a clear path for approval given the lack of existing treatments for negative symptoms [25][26] - **Study Design**: The upcoming study will compare roluperidone to commonly prescribed antipsychotics, using a double-dummy design to maintain blinding [28] Future Outlook - **Timeline for Results**: The first patient in the new study is expected to be enrolled in Q2 of the current year, with top-line results anticipated in the second half of next year [41][42] - **Regulatory Submission**: Following the results, the company plans to re-engage with the FDA regarding NDA submission [42] Additional Considerations - **Clinical Meaningfulness**: The company is working to establish clinically meaningful effect sizes in collaboration with the FDA, given the absence of approved treatments for negative symptoms [30][31] - **Relapse Assessment**: The study will include psychometric endpoints and hard clinical endpoints to assess relapse rates and overall patient safety [39][40]

Core Viewpoint - The approval of Nemonapride Chloride (brand name: Kaijiele) by the National Medical Products Administration marks the first new mechanism treatment for schizophrenia in over 70 years, providing a significant advancement in the management of this chronic mental illness [1][2]. Group 1: Drug Approval and Mechanism - Nemonapride Chloride has been approved for the treatment of adult schizophrenia, representing a novel therapeutic option with a unique mechanism of action [1]. - Unlike existing antipsychotic medications that primarily target dopamine or serotonin receptors, Nemonapride Chloride acts as a combination of M1/M4 muscarinic acetylcholine receptor agonist and antagonist, which may lead to improved efficacy and reduced side effects [2]. Group 2: Clinical Significance - The drug has shown effectiveness in improving positive, negative, and cognitive symptoms of schizophrenia while avoiding common side effects associated with traditional antipsychotics, such as weight gain and extrapyramidal symptoms [2]. - The inclusion of Nemonapride Chloride in the "Chinese Guidelines for the Prevention and Treatment of Schizophrenia (2025 Edition)" as an innovative therapy highlights its significance in clinical practice [2].

Core Viewpoint - Zai Ding Pharmaceutical (ZLAB.US) shares rose over 7% to $18.84, following the approval of a new drug for schizophrenia treatment by the National Medical Products Administration of China, marking a significant breakthrough in the field [1] Company Summary - Zai Ding Pharmaceutical announced the approval of its new drug, Nemonapride Chloride Capsules (Kai Jie Le), for the treatment of adult schizophrenia [1] - This drug represents the first new treatment mechanism for schizophrenia approved in over 70 years, indicating a fundamental advancement in schizophrenia therapy [1] Market Reaction - Following the announcement, Zai Ding Pharmaceutical's stock price increased by 7% in the U.S. market and 6.24% in the Hong Kong market [1]

Core Viewpoint - Green Leaf Pharmaceutical (02186.HK) has signed a cooperation agreement with Jiangsu Enhua Pharmaceutical Co., Ltd. for exclusive commercialization rights of three long-acting injectable antipsychotic products in mainland China [1] Group 1: Agreement Details - The three products involved are Risperidone microspheres (Rykotuo), Paliperidone palmitate injection (Ruibailai), and Paliperidone palmitate injection (Meibiri), all indicated for the treatment of schizophrenia [1] - Enhua will be responsible for the exclusive distribution and commercialization of these products in mainland China, while Green Leaf retains ownership of the assets, registration certificates, and all intellectual property rights [1] - The agreement is set for a duration of ten years, with Enhua making a one-time non-refundable payment of $20 million as a licensing fee to Green Leaf [1] Group 2: Market Implications - This collaboration represents a strong partnership between two leading companies in the central nervous system (CNS) field, aiming to deepen the market presence for schizophrenia treatment [1] - The agreement is expected to provide patients with more comprehensive treatment options in the schizophrenia market [1]

Core Viewpoint - Zai Ding Pharma's stock surged over 6% in Hong Kong, leading to a 4.4% pre-market increase in the US, following the approval of a new drug for schizophrenia treatment by the Chinese National Medical Products Administration, marking a significant breakthrough in the field [1] Group 1: Company Performance - Zai Ding Pharma's closing price was $17.480, with a pre-market price of $18.250, reflecting an increase of $0.770 or 4.41% [2] - The stock reached a high of $18.095 and a low of $17.370 during trading, with a total trading volume of 60.72 million [2] - The company's total market capitalization stands at $1.933 billion, with a total share count of 111 million [2] Group 2: Drug Approval Impact - The newly approved drug, Norepinephrine Chloride Capsule (Kai Jie Le), is the first schizophrenia treatment with a novel mechanism of action approved in over 70 years, representing a fundamental breakthrough in treatment options [1]

Core Viewpoint - Green Leaf Pharmaceutical has signed a collaboration agreement with Jiangsu Enhua Pharmaceutical, granting Enhua exclusive commercialization rights for three long-acting injectable antipsychotic products in mainland China, aimed at enhancing treatment options for schizophrenia patients [1][2]. Group 1: Collaboration Agreement - The agreement includes three products: Rykotan (injectable risperidone microspheres), Rybale (paliperidone palmitate injection), and Meibiri (paliperidone palmitate injection), all intended for the treatment of schizophrenia [1]. - Enhua will be responsible for the exclusive distribution and commercialization of these products in mainland China, while Green Leaf retains ownership of the assets, registration certificates, and all intellectual property rights [1]. - Enhua will pay a non-refundable licensing fee of $20 million to Green Leaf upon signing the agreement, which has a duration of ten years [1]. Group 2: Market Context and Product Development - Schizophrenia is a chronic and highly recurrent disease, with approximately 8 million patients in China, making treatment adherence a significant challenge [2]. - Long-acting injectable antipsychotics, such as those developed by Green Leaf, significantly improve patient compliance compared to oral formulations, serving as an important strategy to prevent relapse [2]. - Rykotan is noted as China's first independently developed long-acting injectable second-generation antipsychotic, while Rybale is the world's first and only paliperidone long-acting injection with a "one injection in the first month" dosing regimen [2]. Group 3: Strategic Importance - The board believes that the three long-acting injectables create a differentiated product portfolio that addresses the treatment needs of schizophrenia patients across all stages of the disease [3]. - The CNS (central nervous system) sector is a core strategic area for Green Leaf, which possesses a competitive product matrix and platform capabilities in this field [3]. - The collaboration with Enhua aims to deepen the market presence in the CNS sector, particularly enhancing product coverage in primary healthcare centers to help more patients receive standardized treatment and reduce the burden of the disease [3].

Core Viewpoint - Green Leaf Pharmaceutical (02186.HK) has signed a cooperation agreement with Jiangsu Enhua Pharmaceutical Co., Ltd. and its subsidiary, Jiangsu Enhua Xinyi Pharmaceutical Marketing Co., Ltd., granting Enhua exclusive commercialization rights for three long-acting injectable antipsychotic products in mainland China [1] Group 1: Agreement Details - The three products involved are Risperidone microspheres (Rykotuo), Paliperidone palmitate injection (Ruibailai), and Paliperidone palmitate injection (Meibiri), all indicated for the treatment of schizophrenia [1] - Enhua will be responsible for the exclusive distribution and commercialization of these products in mainland China, while the group retains ownership of the assets, registration certificates, and all intellectual property rights, as well as responsibility for production and supply [1] - The agreement is set for a duration of ten years, with Enhua making a one-time non-refundable payment of $20 million as a licensing fee to the group [1] Group 2: Strategic Implications - This collaboration represents a strong partnership between two leading companies in the central nervous system (CNS) field, aiming to deepen the market presence in schizophrenia treatment and provide more comprehensive treatment options for patients [1]

Core Viewpoint - Zai Ding Pharmaceutical (09688) has received approval from the National Medical Products Administration (NMPA) for the new drug application of Nemonapride Chloride Capsules (Kai Jie Le), marking a significant breakthrough in the treatment of schizophrenia with a novel mechanism of action, the first in over 70 years [1] Group 1: Company Developments - Zai Ding Pharmaceutical's stock rose over 4% in early trading, currently up 3.45% at HKD 14.1, with a trading volume of HKD 59.19 million [1] - The approval of Nemonapride Chloride Capsules is based on data from Phase I pharmacokinetic studies and Phase III clinical trials conducted in China, as well as three global EMERGENT clinical studies [1] Group 2: Industry Impact - The approval of this new schizophrenia treatment represents a fundamental breakthrough in the field, potentially changing the landscape of schizophrenia therapies [1] - Zai Ding Pharmaceutical acquired exclusive rights to develop, manufacture, and commercialize Nemonapride Chloride Capsules in Greater China from Karuna Therapeutics for USD 187 million in November 2021 [1]

Core Insights - A new method to effectively improve negative symptoms of schizophrenia has been discovered by Dr. Han Yuyi from Harbin First Specialized Hospital, with results published in the international journal "Brain Stimulation" [1][2] Group 1: Research Findings - Schizophrenia patients experience both positive symptoms (hallucinations, delusions) and negative symptoms (emotional flatness, social withdrawal), with the latter often overlooked [1] - Current drug treatments are effective for positive symptoms but show limited efficacy for negative symptoms [1] - Non-invasive neurostimulation techniques, such as transcranial magnetic stimulation, are being explored for treating negative symptoms, but existing methods have significant limitations [1] Group 2: Clinical Study - The study involved 80 schizophrenia patients primarily exhibiting negative symptoms, divided into a true stimulation group and a sham stimulation group [2] - The true stimulation group received individualized accelerated intermittent theta-burst stimulation for 10 days, with four sessions daily, each consisting of 1800 pulses [1][2] - Results showed a significant reduction in negative symptoms in the true stimulation group after four weeks, with a response rate of 77.5% compared to 17.5% in the sham group [2] Group 3: Effectiveness and Future Plans - The average score for negative symptoms in the true stimulation group decreased by 4.10 points, with an effect size of 0.83, indicating moderate to high treatment effectiveness [2] - Neuroactivity changes in the left middle temporal gyrus and weakened functional connectivity between the midbrain and middle temporal gyrus were associated with symptom improvement [2] - Future plans include larger multi-center clinical studies to optimize treatment parameters for broader patient access [2]

Core Insights - The theme for World Mental Health Day 2025 is "Everyone enjoys mental health services," highlighting the increasing challenges in China's mental health sector [1] - The World Health Organization (WHO) reports approximately 24 million schizophrenia patients globally, with over 8 million in China, indicating a significant public health issue [1] - Schizophrenia is increasingly recognized as a chronic brain disease rather than a functional disorder, necessitating long-term treatment strategies [1][2] Treatment Challenges - Approximately 80% of schizophrenia patients experience onset between the ages of 16 and 35, a critical period for social integration [2] - Poor medication adherence is a major challenge in treating schizophrenia, with a treatment interruption rate of 75% in China, leading to high relapse rates of 77% within one year and 90% within two years [3] - Each relapse can increase direct medical costs by four times, emphasizing the need for improved adherence strategies [3] Long-Acting Injectable Medications - The recently updated "Chinese Schizophrenia Prevention and Treatment Guidelines (2025 Edition)" emphasizes the clinical value of long-acting injectable antipsychotics, recommending their early use while respecting patient preferences [4] - Long-acting injectables can significantly reduce medication frequency and improve adherence compared to oral medications [4] - Current clinical usage of long-acting injectables in China is less than 5%, compared to 25%-30% in Europe and the U.S., indicating a substantial gap [5] Government and Healthcare Initiatives - Efforts are underway to increase the clinical use of long-acting injectables in China, including enhanced education for healthcare providers and patients, as well as the inclusion of these medications in health insurance coverage [5] - Government subsidy programs in cities like Shanghai are providing free medication support to patients, aiming to improve treatment access and adherence [5]